News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Phase 2 Study Of Selinexor (KPT-330) Initiated By Karyopharm Therapeutics (KPTI) In Patients With Advanced Gynecologic Malignancies (SIGN Study)



4/24/2014 9:02:25 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NATICK, Mass., April 24, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced the initiation of a Phase 2 trial of its novel, oral Selective Inhibitor of Nuclear Export (SINE) compound Selinexor (KPT-330) in patients with advanced gynecologic malignancies including cervical, ovarian and uterine carcinomas. The study, referred to as the SIGN Study, is being led by Ignace Vergote, MD, at the University Hospitals, Leuven, Belgium. SIGN is also open at Rigshospitalet in Copenhagen, Aalborg University Hospital, Aalborg, and Herlev Hospital, Herlev, all in Denmark.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES